BMS Reports Pooled Five Year Results of Opdivo (nivolumab) in Two P-III Studies for Advanced Non-Small Cell Lung Cancer

BMS Reports Pooled Five Year Results of Opdivo (nivolumab) in Two P-III Studies for Advanced Non-Small Cell Lung Cancer

Shots:

  • The pooled analysis of the two P-III CheckMate -017 and -057 studies involves assessing of Opdivo (3 mg/kg, q2w) vs Docetaxel (75 mg/m2, q3w) in 854 patients in a ratio (1:1) with previously treated NSCLC across both squamous and non-squamous histologies
  • The P-III studies result: @5yrs. OS (13.4% vs 2.6%); patients continued to see response (32.2% vs 0%); m-DoR (19.9 vs 5.6 mos.); no new safety signals with extended follow-up
  • Opdivo is a PD-1 immune checkpoint inhibitor, harnessing the body’s own immune system to restore anti-tumor immune response and is the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world

Click here to­ read full press release/ article | Ref: BMS | Image: Law